Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study

Pharmaceuticals - Tập 8 Số 3 - Trang 512-524
Abigail Hensley1, Ian Beales2,1
1Norwich Medical School, University of East Anglia, Norwich 06360, UK
2Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich 06360, UK

Tóm tắt

Patients with inflammatory bowel disease (IBD) often have associated conditions, for which anti-inflammatory medication with cyclo-oxygenase (COX) inhibitors may be helpful. The current evidence is conflicting regarding the role of COX-inhibitors in causing relapse in IBD. This case-control study examined the association between the use of COX inhibitors and relapse of IBD. Logistic regression was used to analyse the relationship between COX-inhibitors and IBD relapse. Overall COX inhibitor use (combined non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 agents) had a negative association with relapse of IBD (adjusted OR 0.26, 95% CI 0.09–0.80). This negative association was confined to ulcerative colitis (UC) (adjusted OR = 0.06, 95% CI 0.01–0.50) and no association was found in Crohn’s disease (CD) patients (adjusted OR 1.25, 95% CI 0.18–7.46). The significant negative association between UC relapse and medication use was also seen with non-specific NSAIDs. Selective COX-2 inhibitor use was rare but non-significantly more common in stable patients. There was no association between low-dose aspirin or paracetamol use and relapse of CD or UC. We conclude that COX-inhibitor use was not associated with an increased risk of relapse in UC or CD, and may be protective in UC. Where indicated, NSAIDs should not be withheld from IBD patients.

Từ khóa


Tài liệu tham khảo

Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001

Mowat, 2011, Guidelines for the management of inflammatory bowel disease in adults, Gut, 60, 571, 10.1136/gut.2010.224154

Vidal, 2006, Life events and inflammatory bowel disease relapse: A prospective study of patients enrolled in remission, Am. J. Gastroenterol., 101, 775, 10.1111/j.1572-0241.2006.00476.x

Miner, 1997, Factors influencing the relapse of patients with inflammatory bowel disease, Am. J. Gastroenterol., 92, 1S

Smith, 1998, Pharmacological analysis of cyclooxygenase-1 in inflammation, Proc. Natl. Acad. Sci. USA, 95, 13313, 10.1073/pnas.95.22.13313

Johansson, 1982, Prostaglandin and protection of the gastroduodenal mucosa, Scand. J. Gastroenterol. Suppl., 77, 21

Rampton, 1981, Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs, Postgrad. Med. J., 57, 297, 10.1136/pgmj.57.667.297

McCartney, 1999, Selective COX-2 inhibitors and human inflammatory bowel disease, Aliment. Pharmacol. Ther., 13, 1115, 10.1046/j.1365-2036.1999.00585.x

Vane, 1994, Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation, Proc. Natl. Acad. Sci. USA, 91, 2046, 10.1073/pnas.91.6.2046

Levy, 2010, Resolvins and protectins: Natural pharmacophores for resolution biology, Prostaglandins Leukot. Essent. Fatty Acids, 82, 327, 10.1016/j.plefa.2010.02.003

Wallace, 2001, Prostaglandin biology in inflammatory bowel disease, Gastroenterol. Clin. North Am., 30, 971, 10.1016/S0889-8553(05)70223-5

Wang, 2005, The role of prostaglandins and other eicosanoids in the gastrointestinal tract, Gastroenterology, 128, 1445, 10.1053/j.gastro.2004.09.080

Arico, 2002, Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line, J. Biol. Chem., 277, 27613, 10.1074/jbc.M201119200

Beales, 2006, Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways, Mol. Cell Endocrinol., 247, 140, 10.1016/j.mce.2005.12.050

Dovizio, 2012, Mechanistic and pharmacological issues of aspirin as an anticancer agent, Pharmaceuticals, 5, 1346, 10.3390/ph5121346

Rampton, 1983, Analgesic ingestion and other factors preceding relapse in ulcerative colitis, Gut, 24, 187, 10.1136/gut.24.3.187

Pedersen, 2002, Phenol toxicity and conjugation in human colonic epithelial cells, Scand. J. Gastroenterol., 37, 74, 10.1080/003655202753387392

Kankuri, 2001, Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut, Inflammation, 25, 301, 10.1023/A:1012860509440

Felder, 2000, Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study, Am. J. Gastroenterol., 95, 1949, 10.1111/j.1572-0241.2000.02262.x

Takeuchi, 2006, Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease, Clin. Gastroenterol. Hepatol., 4, 196, 10.1016/S1542-3565(05)00980-8

Meyer, 2006, Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs, Dig. Dis. Sci., 51, 168, 10.1007/s10620-006-3103-5

Bonner, 2004, A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease, Inflamm. Bowel. Dis., 10, 751, 10.1097/00054725-200411000-00009

Evans, 1997, Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease, Gut, 40, 619, 10.1136/gut.40.5.619

Bonner, 2000, Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease, Am. J. Gastroenterol., 95, 1946, 10.1111/j.1572-0241.2000.02263.x

Biancone, 2004, Rofecoxib and early relapse of inflammatory bowel disease: An open-label trial, Aliment. Pharmacol. Ther., 19, 755, 10.1111/j.1365-2036.2004.01907.x

Matuk, 2004, The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease, Inflamm. Bowel. Dis., 10, 352, 10.1097/00054725-200407000-00005

Mahadevan, 2002, Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease, Am. J. Gastroenterol., 97, 910, 10.1111/j.1572-0241.2002.05608.x

Reinisch, 2003, An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia, Aliment. Pharmacol. Ther., 17, 1371, 10.1046/j.1365-2036.2003.01596.x

Forrest, 2004, Systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?, Aliment. Pharmacol. Ther., 20, 1035, 10.1111/j.1365-2036.2004.02270.x

Kefalakes, 2009, Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or reality?, Eur. J. Clin. Pharmacol., 65, 963, 10.1007/s00228-009-0719-3

Jose, 2008, Extraintestinal manifestations of inflammatory bowel disease, J. Pediatr. Gastroenterol. Nutr., 46, 124, 10.1097/MPG.0b013e318093f4b0

Stolwijk, 2013, Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease, Can. J. Gastroenterol., 27, 199, 10.1155/2013/139702

Broughton, 2013, Statin use is associated with a reduced incidence of colorectal adenomatous polyps, Int. J. Colorectal. Dis., 28, 469, 10.1007/s00384-012-1601-9

Kantor, 2012, Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett’s esophagus, Cancer Epidemiol. Biomarkers Prev., 21, 456, 10.1158/1055-9965.EPI-11-1014

Harvey, 1980, A simple index of Crohn’s-disease activity, Lancet, 1, 514, 10.1016/S0140-6736(80)92767-1

Best, 2006, Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index, Inflamm. Bowel. Dis., 12, 304, 10.1097/01.MIB.0000215091.77492.2a

Walmsley, 1998, A simple clinical colitis activity index, Gut, 43, 29, 10.1136/gut.43.1.29

Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N. Engl. J. Med., 317, 1625, 10.1056/NEJM198712243172603

Daperno, 2004, Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD, Gastrointest. Endosc., 60, 505, 10.1016/S0016-5107(04)01878-4

Ananthakrishnan, 2012, Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: A cohort study, Ann. Intern. Med., 156, 350, 10.7326/0003-4819-156-5-201203060-00007

Thông tin
Thông tin xuất bản

Pharmaceuticals

Tập 8 Số 3

512-524

Thông tin tác giả